US Stock MarketDetailed Quotes
PROK ProKidney
- 2.000
- +0.150+8.11%
Close Nov 29 13:00 ET
- 1.990
- -0.010-0.50%
Post 13:30 ET
255.94MMarket Cap-3703P/E (TTM)
2.205High1.880Low674.22KVolume1.890Open1.850Pre Close1.40MTurnover0.96%Turnover RatioLossP/E (Static)127.97MShares4.44052wk High-0.26P/B140.78MFloat Cap1.18052wk Low--Dividend TTM70.39MShs Float14.190Historical High--Div YieldTTM17.57%Amplitude1.120Historical Low2.070Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
ProKidney Stock Forum
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...
SEC· 11 mins ago
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
No comment yet